Trastuzumab - StatPearls

Trastuzumab deruxtecan is an effective new treatment for patients with HER2-positive metastatic breast cancer who have been previously treated

Cardiotoxicity Trastuzumab is a monoclonal antibody tyrosine kinase inhibitor that targets the HER2 receptor often over overexpressed or overactive in breast

trastuzumab Self-Care Tips: · Drink at least two to three quarts of fluid every 24 hours, unless you are instructed otherwise · Trastuzumab causes little nausea · You may

trastuzumab trastuzumab emtansine continued to improve invasive disease–free survival and overall survival compared with trastuzumab in patients